ID   M14P
AC   CVCL_U345
SY   M14
DR   Cosmic; 733823
DR   IARC_TP53; 23630
DR   Wikidata; Q54903476
RX   PubMed=1568228;
RX   PubMed=2323006;
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
CC   Transformant: ChEBI; CHEBI_46661; Asbestos.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C45662; Pleural epithelioid mesothelioma
DI   ORDO; Orphanet_50251; Pleural mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_8102 ! M14K
OI   CVCL_8103 ! M20 [Human mesothelioma]
SX   Male
AG   43-61Y
CA   Cancer cell line
DT   Created: 03-02-14; Last updated: 19-12-24; Version: 13
//
RX   PubMed=1568228;
RA   Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A.,
RA   Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I.,
RA   Harris C.C.;
RT   "p53 and Kirsten-ras mutations in human mesothelioma cell lines.";
RL   Cancer Res. 52:2610-2615(1992).
//
RX   PubMed=2323006; DOI=10.1093/carcin/11.4.673;
RA   Pelin-Enlund K., Husgafvel-Pursiainen K., Tammilehto L., Klockars M.,
RA   Jantunen K., Gerwin B.I., Harris C.C., Tuomi T., Vanhala E.,
RA   Mattson K., Linnainmaa K.;
RT   "Asbestos-related malignant mesothelioma: growth, cytology,
RT   tumorigenicity and consistent chromosome findings in cell lines from
RT   five patients.";
RL   Carcinogenesis 11:673-681(1990).
//